Literature DB >> 29959729

A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid.

Xiao-Ling Zhong1, Jie-Qiong Li2, Li Sun1, Ya-Qing Li3, Hui-Fu Wang2,4, Xi-Peng Cao4, Chen-Chen Tan2, Ling Wang1, Lan Tan5,6, Jin-Tai Yu7,8,9.   

Abstract

α-Synuclein is a 140-amino acid protein produced predominantly by neurons in the brain which plays a role in the regulation of neurotransmitter release, synaptic function, and plasticity, thus making it the focus in understanding the etiology of a group of neurodegenerative diseases. We conducted genome-wide association studies (GWAS) of α-synuclein levels in cerebrospinal fluid (CSF) with 209 non-Hispanic white participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI-1) cohort using a linear regression model to identify novel variants associated with α-synuclein concentration. The minor allele (T) of rs7072338 in the long intergenic non-protein coding RNA 1515 (LINC01515) and the minor allele (T) of rs17794023 in clusterin-associated protein 1 (CLUAP1) were associated with higher CSF α-synuclein levels at genome-wide significance (P = 4.167 × 10-9 and 9.56 × 10-9, respectively). In addition, single nucleotide polymorphisms (SNPs) near amyloid beta precursor protein (APP) (rs1394839) (P = 2.31 × 10-7), Rap guanine nucleotide exchange factor 1 (RAPGEF1) (rs10901091) (P = 8.07 × 10-7), and two intergenic loci on chromosome 2 and 14 (rs11687064 P = 2.50 × 10-7and rs7147386 P = 4.05 × 10-7) were identified as suggestive loci associated with CSF α-synuclein levels. We have identified significantly associated SNPs for CSF α-synuclein. These associations have important implications for a better understanding of α-synuclein regulation and allow researchers to further explore the relationships between these SNPs and α-synuclein-related neurodegenerative disorders.

Entities:  

Keywords:  Cerebrospinal fluid; Endophenotype; Genome-wide association studies; α-Synuclein

Mesh:

Substances:

Year:  2018        PMID: 29959729     DOI: 10.1007/s12640-018-9922-2

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  39 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system.

Authors:  Hisamitsu Ishikura; Hiroaki Ikeda; Hiroyuki Abe; Takayuki Ohkuri; Hiroaki Hiraga; Kazuo Isu; Tomohide Tsukahara; Noriyuki Sato; Hidemitsu Kitamura; Norimasa Iwasaki; Naoki Takeda; Akio Minami; Takashi Nishimura
Journal:  Int J Oncol       Date:  2007-02       Impact factor: 5.650

3.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

Authors:  E Masliah; E Rockenstein; I Veinbergs; Y Sagara; M Mallory; M Hashimoto; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

4.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

5.  Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer.

Authors:  Meiko Takahashi; Yu-Min Lin; Yusuke Nakamura; Yoichi Furukawa
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

6.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

7.  Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene.

Authors:  Tiffany A Greenwood; John R Kelsoe
Journal:  Genomics       Date:  2003-11       Impact factor: 5.736

8.  Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

Authors:  Brit Mollenhauer; Valerie Cullen; Ilana Kahn; Bryan Krastins; Tiago F Outeiro; Imelda Pepivani; Juliana Ng; Walter Schulz-Schaeffer; Hans A Kretzschmar; Pamela J McLean; Claudia Trenkwalder; David A Sarracino; Jean-Paul Vonsattel; Joseph J Locascio; Omar M A El-Agnaf; Michael G Schlossmacher
Journal:  Exp Neurol       Date:  2008-06-14       Impact factor: 5.330

9.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  4 in total

1.  Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.

Authors:  David Vogrinc; Katja Goričar; Vita Dolžan
Journal:  Front Aging Neurosci       Date:  2021-03-18       Impact factor: 5.750

2.  Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.

Authors:  Laura Ibanez; Jorge A Bahena; Chengran Yang; Umber Dube; Fabiana H G Farias; John P Budde; Kristy Bergmann; Carol Brenner-Webster; John C Morris; Richard J Perrin; Nigel J Cairns; John O'Donnell; Ignacio Álvarez; Monica Diez-Fairen; Miquel Aguilar; Rebecca Miller; Albert A Davis; Pau Pastor; Paul Kotzbauer; Meghan C Campbell; Joel S Perlmutter; Herve Rhinn; Oscar Harari; Carlos Cruchaga; Bruno A Benitez
Journal:  Acta Neuropathol Commun       Date:  2020-11-19       Impact factor: 7.801

3.  Studying the effect of alpha-synuclein and Parkinson's disease linked mutants on inter pathway connectivities.

Authors:  Sagnik Sen; Ashmita Dey; Ujjwal Maulik
Journal:  Sci Rep       Date:  2021-08-11       Impact factor: 4.379

Review 4.  Ischemic Stroke and Sleep: The Linking Genetic Factors.

Authors:  Lyudmila Korostovtseva
Journal:  Cardiol Ther       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.